Skip to search boxSkip to navigationSkip to main content

Effect of Traumatic Brain Injury, Erythropoietin, and Anakinra on Hepatic Metabolizing Enzymes and Transporters in an Experimental Rat Model

  • Gail D. Anderson(corresponding author)
    ,
  • Todd C. Peterson
    ,
  • Cole Vonder Haar
    ,
  • Fred M. Farin
    ,
  • Theo K. Bammler
    ,
  • James W. MacDonald
*Corresponding author for this work
  • University of Washington
    ,
  • Southern Illinois University
Scholary Output:
Contribution to journal
Article
Research
Peer-review

Open access

Abstract

In contrast to considerable data demonstrating a decrease in cytochrome P450 (CYP) activity in inflammation and infection, clinically, traumatic brain injury (TBI) results in an increase in CYP and UDP glucuronosyltransferase (UGT) activity. The objective of this study was to determine the effects of TBI alone and with treatment with erythropoietin (EPO) or anakinra on the gene expression of hepatic inflammatory proteins, drug-metabolizing enzymes, and transporters in a cortical contusion impact (CCI) injury model. Microarray-based transcriptional profiling was used to determine the effect on gene expression at 24 h, 72 h, and 7 days post-CCI. Plasma cytokine and liver protein concentrations of CYP2D4, CYP3A1, EPHX1, and UGT2B7 were determined. There was no effect of TBI, TBI + EPO, or TBI + anakinra on gene expression of the inflammatory factors shown to be associated with decreased expression of hepatic metabolic enzymes in models of infection and inflammation. IL-6 plasma concentrations were increased in TBI animals and decreased with EPO and anakinra treatment. There was no significant effect of TBI and/or anakinra on gene expression of enzymes or transporters known to be involved in drug disposition. TBI + EPO treatment decreased the gene expression of Cyp2d4 at 72 h with a corresponding decrease in CYP2D4 protein at 72 h and 7 days. CYP3A1 protein was decreased at 24 h. In conclusion, EPO treatment may result in a significant decrease in the metabolism of Cyp-metabolized drugs. In contrast to clinical TBI, there was not a significant effect of experimental TBI on CYP or UGT metabolic enzymes.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Research
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1255-1267 (13 pages)

Journal (Volume, Issue Number)

AAPS Journal (Volume 17, Issue 5)

Publication milestones

  • Published - 09/21/2015

Publication status

Published - 09/21/2015

Publication IDs

  • Scopus: 84939565711
  • PubMed: 26068867

Publication metrics

Metrics

SciVal
FWCI
0.80
SciVal
Author count
8
SciVal
citations
9
SciVal
Paper percentile
66
Fractional count
1
Fractional count
0.13
Fractional count
7
Fractional count
0.88
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
18
Captures
29

Funding Details

The research was supported by a grant from the National Institutes of Health/National Institute of Child, Health and Development (R01 HD061944-01) and by the NIEHS Center for Ecogenetics & Environmental Health (P30ES007033).
FundersFunding numbers
NIEHS Center for Ecogenetics & Environmental Health
-
NIH
-
NIEHS
P30ES007033
NICHD
R01 HD061944-01